Abacus Medicine
Abacus Medicine, a leading player in the pharmaceutical industry, is headquartered in Denmark (DK) and operates extensively across Europe. Founded in 2004, the company has established itself as a key provider of parallel-imported medicines, ensuring access to high-quality pharmaceuticals at competitive prices. Abacus Medicine's core services include sourcing, distributing, and supplying a wide range of prescription medications, with a focus on efficiency and compliance with regulatory standards. The company is renowned for its commitment to quality assurance and has achieved significant milestones, including partnerships with major healthcare providers. With a strong market position, Abacus Medicine continues to innovate in the pharmaceutical supply chain, making it a trusted name in the industry. Its unique approach to parallel imports not only enhances accessibility but also contributes to cost savings for healthcare systems across its operational regions.
DitchCarbon Score
How does Abacus Medicine's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abacus Medicine's score of 32 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Abacus Medicine's reported carbon emissions
In 2023, Abacus Medicine reported total carbon emissions of approximately 216,900 kg CO2e for Scope 1 and about 642,600 kg CO2e for Scope 2. This marked a slight increase in Scope 1 emissions compared to 2022, where they were about 213,700 kg CO2e. The Scope 2 emissions also saw a rise from approximately 601,300 kg CO2e in the previous year. Over the years, Abacus Medicine's emissions have fluctuated, with Scope 1 emissions increasing from about 62,600 kg CO2e in 2018 to 239,000 kg CO2e in 2021, before stabilising in recent years. The company has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, indicating a potential area for future commitment. Overall, while Abacus Medicine has made strides in tracking its emissions, the absence of formal reduction targets suggests that further action may be necessary to align with industry standards for climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 62,600 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | - | - | - | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abacus Medicine is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
